Lindsay A. Renfro, PhD

Professor of Research Population and Public Health Sciences

Children’s Oncology Group Associate Group Statistician

Image of Lindsay A. Renfro, PhD
Is this your profile? Click to edit

Overview

Dr. Lindsay Renfro is a Professor of Research at the University of Southern California and the Associate Group Statistician for Children’s Oncology Group (COG). COG is the pediatric cooperative group member of the NIH/NCI’s National Clinical Trials Network and the world’s largest organization dedicated exclusively to pediatric cancer research. Within COG, Dr. Renfro is also Lead Statistician for the Renal Tumors and Hodgkin Lymphoma Committees, where she leads the design and analysis of therapeutic and biology-driven clinical trials and related projects in pediatric, young adult, and adult cancer. Her expertise and methodological interests include novel trial designs (e.g., adaptive, Bayesian, biomarker-driven, and master protocols); evaluation, validation, and use of surrogate endpoints in clinical trials; and construction, validation, and implementation of disease-specific prognostic calculators for clinical use and decision-making. Outside of USC and COG, Dr. Renfro serves on the Head and Neck Steering Committee and the Adult Late Phase Emphasis Central IRB for NCI. Dr. Renfro also enjoys teaching statistics to non-statisticians, mentoring students, traveling, and enjoying the mountains and beaches of Southern California with her son.

Awards

  • Texas Woman’s University: Hallmark Alumni Award, 2018
  • Mayo Clinic: KL2 Mentored Career Development Award, 2015
    – 2018
  • ENAR / International Biometric Society: Distinguished Student Paper Award, 2011
  • Baylor University: Dean’s Stipend Enhancement Award, 2006
    – 2011
  • National Science Foundation, National Center for Education Statistics: Fellow, National Summer Data Policy Institute, 2010
  • Association for Institutional Research, National Center for Education Statistics: AIR/NCES Graduate Fellowship, 2008
    – 2010
  • Association for Institutional Research: Best Paper Award, 2007
  • Kappa Mu Epsilon National Mathematics Honor Society: Best Paper Award, 2005
  • Texas Woman’s University: Chancellor’s Research Scholar, 2005
  • Texas Woman’s University: Harlan Miller Award and Memorial Scholarship, 2004
    – 2005
  • Texas Instruments: Women in Engineering Award and Scholarship, 2003
    – 2005

Education and Training

  • Texas Woman’s University — B.S. — 05/2005 — Mathematics
  • Rice University — Ph.D. Student — 05/2006 — Statistics
  • Baylor University — M.S. — 12/2007 — Statistics
  • Baylor University — Ph.D. — 03/2011 — Statistics

Research Funding

  • Children’s Oncology Group Statistics and Data Center
    NIH · U10CA180899 · Apr 15, 2014 – Feb 29, 2032 · Role: Co-Investigator

Research Keywords

  • clinical trials
  • adaptive design
  • Bayesian adaptive design
  • biomarker-driven trials
  • basket trials
  • umbrella trials
  • cancer clinical trials
  • pediatric cancer trials
  • Wilms tumor
  • Hodgkin lymphoma
  • cancers affecting adolescent and young adult (AYA) populations
  • surrogate endpoints
  • surrogate endpoint evaluation
  • clinical prediction modeling
  • clinical calculators
  • patient calculators
  • calculator construction and validation

Publications

  • Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma. Blood Adv. 2026 Jan 13; 10(1):183-191.. View in PubMed
  • Enhancing Radiation Therapy Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131. Int J Radiat Oncol Biol Phys. 2026 07 01; 125(3):737-742.. View in PubMed
  • An efficient single-arm Bayesian adaptive trial algorithm to evaluate de-intensified oncologic treatment. Trials. 2025 Dec 10; 27(1):34.. View in PubMed
  • Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children’s Oncology Group Study AREN0533. J Clin Oncol. 2025 12 20; 43(36):3822-3832.. View in PubMed
  • Group-based trajectories of health-related quality of life among pediatric patients with high-risk Hodgkin lymphoma. J Natl Cancer Inst. 2025 Oct 01; 117(10):2112-2119.. View in PubMed
  • Bayesian Adaptive Enrichment Design for Continuous Biomarkers. Stat Med. 2025 Sep; 44(20-22):e70262.. View in PubMed
  • Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination. J Natl Cancer Inst. 2025 Sep 01; 117(9):1764-1773.. View in PubMed
  • Clinical and Pathologic features of 535 Patients with Congenital Mesoblastic Nephroma: A Report from the Children’s Oncology Group. Ann Surg. 2025 Aug 01.. View in PubMed
  • Caregiver At-Work Productivity Loss at the Time of a Child’s Diagnosis With High-Risk Hodgkin Lymphoma: A Report From the Children’s Oncology Group AHOD1331 Study. Pediatr Blood Cancer. 2025 Sep; 72(9):e31841.. View in PubMed
  • Comparison of Contemporary Radiation Therapy Approaches in Combined Modality Treatment on Pediatric High-Risk Classic Hodgkin Lymphoma Study: AHOD 1331. Int J Radiat Oncol Biol Phys. 2025 11 15; 123(4):972-979.. View in PubMed